GeoVax Labs, Inc. (GOVX) stock
GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.71−0.33 (-16.42%)
Close on Nov 13, 2026Market cap $717.73KP/E –Yield –
GeoVax Labs r&d expenses
Research and development expenses are spending on new products and technology.
GeoVax Labs's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.83M, down 43.6% year over year. For fiscal 2025 it was $18.12M, down 23.6% from the year before. Over ten years it grew 26.8% a year on average. The highest annual figure on record is $23.71M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.12M | -23.6% |
| FY2024 | Dec 31, 2024 | $23.71M | +14.4% |
| FY2023 | Dec 31, 2023 | $20.72M | +127.1% |
| FY2022 | Dec 31, 2022 | $9.12M | -41.3% |
| FY2021 | Dec 31, 2021 | $15.55M | +536.3% |
| FY2020 | Dec 31, 2020 | $2.44M | +27.9% |
| FY2019 | Dec 31, 2019 | $1.91M | +1.7% |
| FY2018 | Dec 31, 2018 | $1.88M | -6.9% |
| FY2017 | Dec 31, 2017 | $2.02M | +2.4% |
| FY2016 | Dec 31, 2016 | $1.97M | +16.4% |
| FY2015 | Dec 31, 2015 | $1.69M | -6.6% |
| FY2014 | Dec 31, 2014 | $1.81M | -37.8% |
| FY2013 | Dec 31, 2013 | $2.91M | -4.2% |
| FY2012 | Dec 31, 2012 | $3.04M | -28.8% |
| FY2011 | Dec 31, 2011 | $4.28M | -10.8% |
| FY2010 | Dec 31, 2010 | $4.79M | +17.8% |
| FY2009 | Dec 31, 2009 | $4.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.82M | -44.1% |
| Q2 FY2026 | Jun 30, 2026 | $3.11M | -34.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.90M | -27.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.99M | -60.6% |
| Q3 FY2025 | Sep 30, 2025 | $5.04M | -31.9% |
| Q2 FY2025 | Jun 30, 2025 | $4.73M | +10.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.35M | +21.0% |
| Q4 FY2024 | Dec 31, 2024 | $7.61M | +22.0% |
| Q3 FY2024 | Sep 30, 2024 | $7.40M | +6.5% |
| Q2 FY2024 | Jun 30, 2024 | $4.28M | -9.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.43M | +57.0% |
| Q4 FY2023 | Dec 31, 2023 | $6.23M | +65.6% |
| Q3 FY2023 | Sep 30, 2023 | $6.95M | +155.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.72M | +261.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.82M | +111.9% |
| Q4 FY2022 | Dec 31, 2022 | $3.76M | -70.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.72M | +122.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.31M | +57.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.33M | +120.7% |
| Q4 FY2021 | Dec 31, 2021 | $12.89M | +1602.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.22M | +193.8% |
| Q2 FY2021 | Jun 30, 2021 | $832.84K | +80.5% |
| Q1 FY2021 | Mar 31, 2021 | $602.78K | -25.5% |
| Q4 FY2020 | Dec 31, 2020 | $757.35K | +73.7% |
| Q3 FY2020 | Sep 30, 2020 | $416.76K | -10.9% |
| Q2 FY2020 | Jun 30, 2020 | $461.42K | +2.3% |
| Q1 FY2020 | Mar 31, 2020 | $808.94K | +45.6% |
| Q4 FY2019 | Dec 31, 2019 | $436.10K | -5.6% |
| Q3 FY2019 | Sep 30, 2019 | $467.67K | -16.1% |
| Q2 FY2019 | Jun 30, 2019 | $451.23K | +21.2% |
| Q1 FY2019 | Mar 31, 2019 | $555.72K | +14.1% |
| Q4 FY2018 | Dec 31, 2018 | $461.76K | +2.8% |
| Q3 FY2018 | Sep 30, 2018 | $557.70K | +11.9% |
| Q2 FY2018 | Jun 30, 2018 | $372.20K | -28.2% |
| Q1 FY2018 | Mar 31, 2018 | $486.99K | -11.7% |
| Q4 FY2017 | Dec 31, 2017 | $449.26K | -0.5% |
| Q3 FY2017 | Sep 30, 2017 | $498.20K | – |
| Q2 FY2017 | Jun 30, 2017 | $518.10K | – |
| Q1 FY2017 | Mar 31, 2017 | $551.80K | – |
| Q4 FY2016 | Dec 31, 2016 | $451.34K | – |
See a number that looks wrong?